Inventor · disambiguated record
Zahra Shahrokh
Also filed as: SHAHROKH ZAHRA
39 granted patents·26 pending applications·2,151 citations·filing 1998–2025
98Inventor score
Files withSHIRE HUMAN GENETIC THERAPIES18GENENTECH INC17TAKEDA PHARMACEUTICALS CO7KINIKSA PHARMACEUTICALS LTD5FLORES HEATHER2
Top patents by PatentIndex Score
65 records- 0197US7122636B1Antibody fragment-polymer conjugates and uses of sameGENENTECH INC·Filed 2000·Granted Oct 17, 2006·134 cites·22 claims
- 0297US6171586B1Antibody formulationGENENTECH INC·Filed 1998·Granted Jan 9, 2001·1.6k cites·29 claims
- 0394US7214776B2Antibody fragment-polymer conjugates and uses of sameGENENTECH INC·Filed 2005·Granted May 8, 2007·26 cites·20 claims
- 0493US7507405B2Antibody fragment-polymer conjugates and uses of sameGENENTECH INC·Filed 2006·Granted Mar 24, 2009·19 cites·6 claims
- 0593US2025161417A1Methods and compositions for cns delivery of arylsulfatase aTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 0693US2025121040A1Methods and compositions for cns delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 0792US9220677B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Dec 29, 2015·16 cites·27 claims
- 0892US8545837B2Methods and compositions for CNS delivery of iduronate-2-sulfataseZHU GAOZHONG·Filed 2011·Granted Oct 1, 2013·38 cites·30 claims
- 0992US7842789B2Antibody fragment-polymer conjugates and uses of sameGENENTECH INC·Filed 2008·Granted Nov 30, 2010·14 cites·36 claims
- 1092US6468532B1Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugatesGENENTECH INC·Filed 1999·Granted Oct 22, 2002·95 cites·23 claims
- 1192US2025375506A1Cns delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 1291US11065308B2Methods and compositions for CNS delivery of heparan n-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted Jul 20, 2021·6 cites·5 claims
- 1391US10456454B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Oct 29, 2019·6 cites·27 claims
- 1491US9283181B2CNS delivery of therapeutic agentsCALIAS PERICLES·Filed 2011·Granted Mar 15, 2016·34 cites·6 claims
- 1591US7833766B2Stabilized compositions of proteins having a free thiol moietySHIRE HUMAN GENETIC THERAPIES·Filed 2007·Granted Nov 16, 2010·13 cites·38 claims
- 1691US7005504B2Antibody fragment-peg conjugatesGENENTECH INC·Filed 2000·Granted Feb 28, 2006·30 cites·15 claims
- 1790US10660944B2Stable formulations for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted May 26, 2020·5 cites·23 claims
- 1889US11471516B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Oct 18, 2022·1 cites·17 claims
- 1987US8147830B2Antibody fragment-polymer conjugates and uses of sameHSEI VANESSA·Filed 2010·Granted Apr 3, 2012·9 cites·3 claims
- 2086US11260112B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Mar 1, 2022·2 cites·17 claims
- 2186US9320711B2Methods and compositions for CNS delivery of heparan N-sulfataseNATOLI FARAH·Filed 2011·Granted Apr 26, 2016·22 cites·43 claims
- 2285US12409210B2CNS delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Sep 9, 2025·0 cites·5 claims
- 2385US2025114449A1Stable anti-osmr antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 2483US8673298B2Stabilized compositions of proteins having a free thiol moeityZHU GAOZHONG·Filed 2010·Granted Mar 18, 2014·6 cites·29 claims
- 2581US12121569B2Methods and compositions for CNS delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 22, 2024·0 cites·15 claims
- 2680US9770410B2Methods and compositions for CNS delivery of arylsulfatase ASALAMAT-MILLER NAZILA·Filed 2011·Granted Sep 26, 2017·10 cites·32 claims
- 2779US12161702B2Methods and compositions for CNS delivery of heparan N-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Dec 10, 2024·0 cites·19 claims
- 2879US7741285B2APO-2 ligand/trail formulationsGENENTECH INC·Filed 2005·Granted Jun 22, 2010·2 cites·30 claims
- 2975US12168041B2Methods and compositions for CNS delivery of arylsulfatase ATAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Dec 17, 2024·0 cites·6 claims
- 3075US6458355B1Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugatesGENENTECH INC·Filed 1998·Granted Oct 1, 2002·50 cites·34 claims
- 3174US11141479B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2019·Granted Oct 12, 2021·0 cites·19 claims
- 3273US10646554B2Methods and compositions for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted May 12, 2020·0 cites·19 claims
- 3373US2022062414A1Stable Anti-OSMR Antibody FormulationKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 3470US12383620B2Phthalocyanine dye conjugate compositionsRAKUTEN MEDICAL INC·Filed 2019·Granted Aug 12, 2025·0 cites·8 claims
- 3569US2025325669A1Phthalocyanine dye conjugate compositionsRAKUTEN MEDICAL INC·Filed 2025·Application pending·0 cites
- 3668US10493149B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2018·Granted Dec 3, 2019·0 cites·19 claims
- 3767US10391170B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2018·Granted Aug 27, 2019·0 cites·16 claims
- 3863US7842668B1Apo-2 ligand/trail formulationsGENENTECH INC·Filed 2006·Granted Nov 30, 2010·0 cites·14 claims
- 3963US2017042977A1Methods and compositions for cns delivery of heparan n-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Application pending·0 cites
- 4062US9072785B2Stabilized compositions of proteins having a free thiol moietySHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Jul 7, 2015·0 cites·31 claims
- 4162US7741282B2ApO2 ligand/TRAIL formulationsGENENTECH INC·Filed 2002·Granted Jun 22, 2010·2 cites·32 claims
- 4262US2016158324A1Methods and compositions for cns delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Application pending·0 cites
- 4361US2020237883A1Stable formulations for cns delivery of arylsulfatase aSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 4460US6870033B1Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodiesGENENTECH INC·Filed 1998·Granted Mar 22, 2005·18 cites·10 claims
- 4560US2010291060A1Subcutaneous administration of alpha-galactosidase aSHIRE HUMAN GENETIC THERAPIES·Filed 2008·Application pending·0 cites
- 4659US8652468B2Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugatesHSEI VANESSA·Filed 2012·Granted Feb 18, 2014·0 cites·19 claims
- 4759US2014377244A1Stable formulations for cns delivery of arylsulfatase aSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Application pending·0 cites
- 4858US7855066B1Methods for making Apo-2 ligand using divalent metal ionsGENENTECH INC·Filed 2006·Granted Dec 21, 2010·0 cites·8 claims
- 4958US2022040301A1Anti-IL-6 Antibody FormulationNOVO NORDISK AS·Filed 2021·Application pending·0 cites
- 5058US2018104314A1Stabilized compositions of proteins having a free thiol moietySHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
Showing the top 50 of 65 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zahra Shahrokh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →